Telisotuzumab  (Synonyms: 特立妥珠单抗; ABT-700)

Telisotuzumab (ABT-700) is a human recombinant bivalent antibody, a therapeutic antibody against the hepatocyte growth factor receptor (MET) that binds c-Met with high affinity and inhibits c-Met signaling. Telisotuzumab has antitumor activity^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

Telisotuzumab (ABT-700) (10 μg/mL, 24 h) 可以抑制 SNU5 细胞的增殖，并导致促凋亡的 Bim 增加和抗凋亡的 Bcl-xL 减少，从而诱发细胞凋亡^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Telisotuzumab (ABT-700) (i.p., 2.5-40 mg/kg, twice a week, 90 days) 有效拮抗构成性激活的 c-Met 和下游信号，从而抑制 Hs746T 细胞 SCID 小鼠的肿瘤生长^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1781223-80-0

液体

Colorless to light yellow

特立妥珠单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow cytometry analysis of cMet overexpression CHOK1 cells labelling cMet with Telisotuzumab at 20 nM (Red). Goat anti human IgG Fc (Alexa Fluor488) was used as the secondary antibody at 1/1000 dilution. Isotype control - human IgG (Blue). Unlabeled control - Unlabelled cells (Gray).
• 
  Immobilized HGFR Protein, Human (His) can bind Telisotuzumab. The EC₅₀ for this effect is 65.95 ng/mL.

• [1]. Jieyi Wang, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification. BMC Cancer. 2016 Feb 16;16:105.  [Content Brief]